In­cyte se­cures sec­ond FDA ap­proval for bile duct can­cer drug in mu­tat­ed can­cer type

In­cyte nabbed its sec­ond ap­proval from fed­er­al reg­u­la­tors for can­cer drug pemi­ga­tinib, brand­ed as Pe­mazyre — as the po­ten­tial for even more in­di­ca­tions await.

The com­pa­ny, head­ed by CEO Hervé Hop­penot, put out word be­fore the mar­ket opened on Fri­day that the FDA ap­proved Pe­mazyre un­der pri­or­i­ty re­view for re­lapsed or re­frac­to­ry myeloid/lym­phoid neo­plasms (MLNs) with FGFR1 re­arrange­ment. The drug, an FGFR1/2/3 in­hibitor, was orig­i­nal­ly ap­proved back in 2020 for cholan­gio­car­ci­no­ma, al­so known as bile duct can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER